Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ilya Zubkov
FREE
Ilya Zubkov
Freedom Capital Markets
Wall Street Analyst
★★☆☆☆
#2091
on 13Foresight · ranked by our own returns
40%
Success Rate
-8.2%
Average Return
6 of 15 calls profitable · -21.1% vs benchmark
📈 Across the calls we could measure, roughly 40% of Ilya Zubkov's ratings turned a profit when each position was held for 1 year — averaging -8.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

13 Buy 4 Hold 0 Sell
Ilya's Stock Coverage 17 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
SMTI
Sanara MedTech
 Jun 17, 2026 BUY Strong Buy
+77.2% avg upside
5 analysts
$35.00
58.86% Upside
 ·
SION
Sionna Therapeutics, Inc.
 May 20, 2026 HOLD Strong Buy
+45.8% avg upside
11 analysts
 — -5.6%
ATYR
aTyr Pharma
 May 20, 2026 BUY Buy
+2016.8% avg upside
17 analysts
$3.50
676.89% Upside
 ·
ATRA
Atara Biotherapeutics
 May 18, 2026 HOLD Buy
+79.8% avg upside
18 analysts
$10.00
0.66% Downside
 +5.7%
AMGN
Amgen
 May 07, 2026 BUY Buy
-11.6% avg upside
57 analysts
$375.00
11.10% Upside
 +6.5%
BIIB
Biogen
 May 01, 2026 BUY Strong Buy
+25.1% avg upside
51 analysts
$245.00
24.67% Upside
 +6.2%
INGN
Inogen
 Apr 07, 2026 BUY Buy
+285.2% avg upside
7 analysts
$12.00
87.16% Upside
 -6.0%
ANGO
AngioDynamics
 Apr 06, 2026 BUY Strong Buy
+40.3% avg upside
9 analysts
$16.00
31.61% Upside
 +23.5%
GOCOQ
GoHealth
 Apr 06, 2026 HOLD Hold
+3352.4% avg upside
11 analysts
$1.50
328.54% Upside
 ·
IRMD
Iradimed
 Apr 02, 2026 BUY Strong Buy
-9.2% avg upside
6 analysts
$116.00
25.75% Upside
 -9.8%
INTS
Intensity Therapeutics, Inc.
 Mar 30, 2026 BUY Strong Buy
+1441.3% avg upside
6 analysts
$20.00
410.26% Upside
 -18.5%
BDTX
Black Diamond Therapeutics
 Sep 30, 2025 BUY Strong Buy
+987.8% avg upside
12 analysts
$6.00
261.50% Upside
 -27.4%
SRPT
Sarepta Therapeutics
 Aug 11, 2025 BUY Buy
+246.5% avg upside
49 analysts
$37.00
110.97% Upside
 -12.2%
OWLT
Owlet
 Aug 04, 2025 BUY Strong Buy
+145.5% avg upside
10 analysts
$11.00
119.98% Upside
 -34.7%
CADL
Candel Therapeutics
 Jul 14, 2025 BUY Strong Buy
+112.6% avg upside
10 analysts
$13.00
56.35% Upside
 +35.7%
ELMD
Electromed
 Jul 01, 2025 BUY Strong Buy
-14.4% avg upside
6 analysts
$29.00
25.08% Downside
 +15.1%
LFMD
LifeMD
 Mar 18, 2025 BUY Strong Buy
+145.1% avg upside
13 analysts
$13.00
173.71% Upside
 -27.3%
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Ilya Zubkov — Frequently Asked Questions
How accurate are Ilya Zubkov's stock ratings?
Based on the calls 13Foresight could measure, about 40% of Ilya's ratings were profitable over a one-year hold, with an average return of -8.2% per rating, or -21.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Ilya ranked on 13Foresight?
Ilya Zubkov is currently ranked #2091 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ilya cover?
Ilya most recently has ratings on SMTI, SION, ATYR, ATRA, AMGN, BIIB, INGN, ANGO, GOCOQ, IRMD, INTS, BDTX and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.